Leading Israeli HMO Maccabi Healthcare Services today announced that it is making its technology-driven health value-added knowledge base, which it currently uses to manage over 30 million patient-HMO interactions annually among its 1,7 million members - more than one-quarter of Israel's total population available for adoption by HMOs worldwide. 
Increasing integration in the European healthcare industry is creating the need for a single point of contact for healthcare IT (HIT) systems, which in turn, is driving the market for HIT platforms. Across Europe, healthcare providers are in search of a single, unified platform for clinical and administrative solutions and healthcare IT vendors with comprehensive product portfolios are attempting to address these needs though individual as well as group solutions. 
A new monthly eNewsletter will be delivered to healthcare ICT professionals across the Europe, Middle East and Africa (EMEA) region from mid-February 2007.
Produced by the Healthcare Information and Management Systems Society (HIMSS) the eMessenger service will focus on one topical aspect of healthcare ICT each month and include a specially commissioned interviews with two experts in that field.
The RHÖN-KLINIKUM AG and Siemens Medical Solutions signed a contract just over a year ago for the construction and operation of a particle therapy facility. With the permit approval process and application hearing now underway, the high-tech project is beginning to take shape. Construction is expected to begin in the summer of 2007. Suppliers in the highly competitive and fragmented European virtual screening market face challenges such as limited scientific audience and the lack of common technology standards. Also, despite the high demand for software tools, companies need to develop and introduce the right kind of tools and solutions to broaden their customer base. Siemens Medical Solutions today opened the doors to a new state-of-the-art research facility dedicated exclusively to the development of molecular imaging biomarkers, which will become in vivo diagnostic tools for identifying debilitating diseases such as cancer, and neurological diseases at their earliest stages.